As JNK can upregulate ProT in hepatocellular carcinoma cells [62], treatment with a JNK inhibitor decreases the stability of ProT and increases their susceptibility to cisplatin [62]. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.